Weekly Top News – Psoriasis – September 14, 2020

sonelokinab (M1095) / EMD Serono, AvillionAvillion announces positive top-line results of Phase 2 trial of sonelokinab (M1095), an anti-IL-17 A/F Nanobody, in chronic psoriasis (PRNewswire) - Sep 10, 2020 - P2, N=313; NCT03384745; Sponsor: Bond Avillion 2 Development LP; "Avillion...announces the successful completion and positive top-line results of its Phase 2 trial of sonelokinab (M1095), an investigational anti-IL-17 A/F Nanobody, in patients with moderate to severe chronic plaque-type psoriasis. The study evaluated four dose regimens of sonelokinab, placebo and a reference arm of secukinumab....After completing enrolment of 313 patients, ahead of schedule, the trial met its primary endpoint based on Investigator's Global Assessment (IGA) at week 12, and secondary endpoints (Psoriasis Area and Severity Index or PASI 75, PASI 90, and PASI 100 at week 12) with high statistical significance (p

Skyrizi (risankizumab) / AbbVie, Boehringer IngelheimA Study to Assess Usability of Risankizumab Autoinjector Combination Product in Participants With Moderate to Severe Plaque Psoriasis (clinicaltrials.gov) - Sep 8, 2020 - P3; N=108; Completed; Sponsor: AbbVie; Active, not recruiting --> Completed

Siliq (brodalumab) / Bausch Health, LEO Pharma, Kyowa Hakko KirinEMBRACE 1: Efficacy and Safety of Brodalumab in Adolescents From 12 to 17 Years of Age With Moderate-to-severe Plaque Psoriasis (clinicaltrials.gov) - Sep 11, 2020 - P3; N=120; Not yet recruiting; Sponsor: LEO Pharma; Trial completion date: Nov 2023 --> May 2024; Initiation date: Sep 2020 --> Apr 2021; Trial primary completion date: Jan 2023 --> Jun 2023

Siliq (brodalumab) / Bausch Health, LEO Pharma, Kyowa Hakko KirinAdjusted Brodalumab Dose Compared With Standard Brodalumab Dose in Subjects With Moderate-to-severe Plaque Psoriasis and ≥120 kg Body Weight (clinicaltrials.gov) - Sep 11, 2020 - P4; N=384; Not yet recruiting; Sponsor: LEO Pharma; Trial completion date: Aug 2024 --> Nov 2025; Initiation date: Jun 2020 --> Apr 2021; Trial primary completion date: Apr 2024 --> Jun 2025Clinical • Trial completion date • Trial initiation date • Trial primary completion date